Skip to content

The effect of atorvastatin on patients with multiple sclerosis

The effect of atorvastatin on the disease process in patients with multiple sclerosis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015071323184N1
Enrollment
60
Registered
2015-08-08
Start date
2011-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis (of):generalized

Interventions

Intervention 1: The control group: There was no intervention and patients had received the routine treatment. The routine treatment was prescribed due to the doctor's viewpoint and based on disease sy
Treatment - Drugs
The control group: There was no intervention and patients had received the routine treatment. The routine treatment was prescribed due to the doctor's viewpoint and based on disease symptoms and the p
The Case group: In case group, patients in addition to routine therapy were treated with oral Atorvastatin 80 mg daily for one year.

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Informed consent for entering the study and Fill out the form informed consent; MS disease Exclusion criteria: Side effects of the drug

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Cerebellar function. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.;Visual function. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.;Sensory function. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.;Digestive function - bladder. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.

Secondary

MeasureTime frame
Sensitivity to drug. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ghasami

Arak University of Medical Sciences Neurology Department

k.ghasami@arakmu.ac.ir+86 32222003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026